Thursday, 19 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
World COPD Day was on Wednesday 18 November · #WorldCOPDDay Our coverage →
New Paper Alert

Real-world PFS after selective RET TKI in RET+ NSCLC was 5.9 months with chemotherapy, 6.8 with chemo-immunotherapy

Stephen V Liu summarised outcomes after selective TKI treatment in RET-positive NSCLC, reporting short progression-free survival and no responses to third-line therapy.

“Huge unmet need remains.”— Stephen V Liu, MD

Stephen V Liu, chief of hematology and oncology at Georgetown and MedStar Georgetown University Hospital, summarised outcomes after selective TKI treatment in RET-positive non-small cell lung cancer (NSCLC) in a post on X. He tagged the AACR journal account @CCR_AACR.

According to Liu, the response rate with subsequent therapy was 41%. Real-world progression-free survival (rwPFS) was 5.9 months with chemotherapy and 6.8 months with chemotherapy plus immunotherapy. Real-world overall survival (rwOS) was 18.5 months and 13.7 months respectively. Liu noted that the difference was not significant (p=ns).

Third-line therapy was most often a taxane, Liu wrote. In that setting rwPFS was 1.5 months and the response rate was 0%.

Liu concluded: "Huge unmet need remains."

Original source

#lung-cancer#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.